{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "collapsed": true
   },
   "source": [
    "# Annotate Putative Somatic Variants with CIViC and VEP"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Welcome back to OpenCAP Jupyter Notebooks! Here you can run pre-designed code to generate an output report for your variants. \n",
    "\n",
    "To run Jupyter notebook cells hold-down on \"shift\" and select \"enter\"."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Commands to annotate variants"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "We have created a python script called identified_variants_to_annotation.py that will take in variants from the sequencing pipeline and output a document with annotation information. The output will include variant effect predictions and clinical interpretations of variants in cancer.\n",
    "\n",
    "Before running this cell, please upload your somatic variants to the home directory (see ReadTheDocs) and change the input variant list name to match your somatic variant list. You can run the cell by holding the \"shift\" key and selecting \"enter\"."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'id': 1088, 'name': 'EID1088', 'description': '1325 HER2-positive breast cancer patients treated with trastuzumab and chemotherapy from the N9831 clinical trial were analyzed. There was no statistical difference in disease-free survival between trastuzumab-treated patients who had the FCGR2A 131 H/H high-affinity genotype and patients without that genotype.', 'disease': {'id': 22, 'name': 'Breast Cancer', 'display_name': 'Breast Cancer', 'doid': '1612', 'url': 'http://www.disease-ontology.org/?id=DOID:1612'}, 'drugs': [], 'rating': 4, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'N/A', 'evidence_direction': 'Does Not Support', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 747, 'name': 'Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.', 'citation': 'Norton et al., 2014, Cancer Immunol Res', 'citation_id': '24989892', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/24989892', 'open_access': True, 'pmc_id': 'PMC4215796', 'publication_date': {'year': 2014, 'month': 10}, 'journal': 'Cancer Immunol Res', 'full_journal_title': 'Cancer immunology research', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 456, 'phenotypes': []}\n",
      "{'id': 1084, 'name': 'EID1084', 'description': 'A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival.', 'disease': {'id': 22, 'name': 'Breast Cancer', 'display_name': 'Breast Cancer', 'doid': '1612', 'url': 'http://www.disease-ontology.org/?id=DOID:1612'}, 'drugs': [], 'rating': 3, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'N/A', 'evidence_direction': 'Does Not Support', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 744, 'name': 'ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.', 'citation': 'Kim et al., 2012, Oncology', 'citation_id': '22906996', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/22906996', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2012}, 'journal': 'Oncology', 'full_journal_title': 'Oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 456, 'phenotypes': []}\n",
      "{'id': 1317, 'name': 'EID1317', 'description': 'In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77.', 'disease': {'id': 160, 'name': 'Renal Cell Carcinoma', 'display_name': 'Renal Cell Carcinoma', 'doid': '4450', 'url': 'http://www.disease-ontology.org/?id=DOID:4450'}, 'drugs': [{'id': 157, 'name': 'Sunitinib', 'pubchem_id': None}], 'rating': 3, 'evidence_level': 'B', 'evidence_type': 'Predictive', 'clinical_significance': 'Adverse Response', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 914, 'name': 'Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.', 'citation': 'van Erp et al., 2009, J. Clin. Oncol.', 'citation_id': '19667267', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/19667267', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2009, 'month': 9, 'day': 10}, 'journal': 'J. Clin. Oncol.', 'full_journal_title': 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 540, 'phenotypes': []}\n",
      "{'id': 1302, 'name': 'EID1302', 'description': 'Large meta-analysis of 5,191 breast cancer patients and 3,834 controls did not find a conclusive link between codon 72 allele and breast cancer susceptibility. Odds ratios were 0.98 (95% CI, 0.91–1.05) for heterozygotes and 0.97 (95% CI, 0.86–1.11) in homozygotes (per-allele OR, 0.98; 95% CI, 0.91–1.04). Median age of onset was also not different between genotypes (GG: 49 years, GC: 50, CC: 50).', 'disease': {'id': 22, 'name': 'Breast Cancer', 'display_name': 'Breast Cancer', 'doid': '1612', 'url': 'http://www.disease-ontology.org/?id=DOID:1612'}, 'drugs': [], 'rating': 4, 'evidence_level': 'B', 'evidence_type': 'Predisposing', 'clinical_significance': 'Positive', 'evidence_direction': 'Does Not Support', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 895, 'name': 'Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.', 'citation': 'Schmidt et al., 2007, Cancer Res.', 'citation_id': '17909070', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/17909070', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2007, 'month': 10, 'day': 1}, 'journal': 'Cancer Res.', 'full_journal_title': 'Cancer research', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 531, 'phenotypes': []}\n",
      "{'id': 1304, 'name': 'EID1304', 'description': 'In a relatively small meta-analysis of 119 women with cervical cancer and 127 controls, associations with homozygosity for arginine, and heterozygosity at this locus were both associated with odds ratios above one (3.5 and 2.2, respectively) after adjusting for age and HPV infection. However, both confidence intervals had minimums below one (0.9 and 0.6, respectively). So the overall conclusion remains mixed on the significance of this polymorphism in the prognosis for cervical cancer.', 'disease': {'id': 159, 'name': 'Cervical Cancer', 'display_name': 'Cervical Cancer', 'doid': '4362', 'url': 'http://www.disease-ontology.org/?id=DOID:4362'}, 'drugs': [], 'rating': 2, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'Poor Outcome', 'evidence_direction': 'Does Not Support', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 897, 'name': 'TP53 polymorphism, HPV infection, and risk of cervical cancer.', 'citation': 'Klug et al., 2001, Cancer Epidemiol. Biomarkers Prev.', 'citation_id': '11535556', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/11535556', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2001, 'month': 9}, 'journal': 'Cancer Epidemiol. Biomarkers Prev.', 'full_journal_title': 'Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 531, 'phenotypes': []}\n",
      "{'id': 1303, 'name': 'EID1303', 'description': 'Pooled data from 13 studies of patients with lung cancer found little effect of codon 72 allele on the overall survival of patients with lung cancer. Proline homozygous patients were correlated with slightly poorer outcome, odds ratio 1.18 with a 95% confidence interval of 0.99-1.41. Heterozygotes had an OR of 1.02 (95% CI 0.86-1.20). Authors conclude that the effect of these alleles on prognosis in lung cancer is inconclusive at best.', 'disease': {'id': 152, 'name': 'Lung Carcinoma', 'display_name': 'Lung Carcinoma', 'doid': '3905', 'url': 'http://www.disease-ontology.org/?id=DOID:3905'}, 'drugs': [], 'rating': 3, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'Poor Outcome', 'evidence_direction': 'Does Not Support', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 896, 'name': 'TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.', 'citation': 'Matakidou et al., 2003, Mutagenesis', 'citation_id': '12840112', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/12840112', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2003, 'month': 7}, 'journal': 'Mutagenesis', 'full_journal_title': 'Mutagenesis', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 531, 'phenotypes': []}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'id': 673, 'name': 'EID673', 'description': 'The XRCC1 R399Q variant was correlated with increased response to platinum-based neoadjuvant chemotherapy in patients with cervical cancer. Tumor samples from 36 patients with Stage IB or IIA bulky (greater than 4 cm in size) cervical carcinomas were used in this study.', 'disease': {'id': 159, 'name': 'Cervical Cancer', 'display_name': 'Cervical Cancer', 'doid': '4362', 'url': 'http://www.disease-ontology.org/?id=DOID:4362'}, 'drugs': [{'id': 326, 'name': 'Cisplatin', 'pubchem_id': None}, {'id': 93, 'name': 'Carboplatin', 'pubchem_id': None}], 'rating': 4, 'evidence_level': 'B', 'evidence_type': 'Predictive', 'clinical_significance': 'Sensitivity/Response', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Mutation', 'drug_interaction_type': 'Substitutes', 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 907, 'name': 'XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.', 'citation': 'Chung et al., 2006, Gynecol. Oncol.', 'citation_id': '16875718', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/16875718', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2006, 'month': 12}, 'journal': 'Gynecol. Oncol.', 'full_journal_title': 'Gynecologic oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 261, 'phenotypes': []}\n",
      "{'id': 672, 'name': 'EID672', 'description': 'The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.', 'disease': {'id': 8, 'name': 'Non-small Cell Lung Carcinoma', 'display_name': 'Non-small Cell Lung Carcinoma', 'doid': '3908', 'url': 'http://www.disease-ontology.org/?id=DOID:3908'}, 'drugs': [], 'rating': 4, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'Better Outcome', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Mutation', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 427, 'name': 'Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.', 'citation': 'Liao et al., 2012, J Thorac Oncol', 'citation_id': '22551904', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/22551904', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2012, 'month': 6}, 'journal': 'J Thorac Oncol', 'full_journal_title': 'Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 261, 'phenotypes': []}\n",
      "{'id': 677, 'name': 'EID677', 'description': 'The ERCC2 K751Q variant is significantly correlated with increased response to paclitaxel and carboplatin therapies in non small cell lung cancer (NSCLC). The researchers utilized data from three previous clinical trials in Japan and the United States with a total of 526 NSCLC patients.', 'disease': {'id': 8, 'name': 'Non-small Cell Lung Carcinoma', 'display_name': 'Non-small Cell Lung Carcinoma', 'doid': '3908', 'url': 'http://www.disease-ontology.org/?id=DOID:3908'}, 'drugs': [{'id': 93, 'name': 'Carboplatin', 'pubchem_id': None}, {'id': 81, 'name': 'Paclitaxel', 'pubchem_id': None}], 'rating': 3, 'evidence_level': 'B', 'evidence_type': 'Predictive', 'clinical_significance': 'Sensitivity/Response', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Mutation', 'drug_interaction_type': 'Combination', 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 431, 'name': 'Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.', 'citation': 'Gandara et al., 2009, J. Clin. Oncol.', 'citation_id': '19470925', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/19470925', 'open_access': True, 'pmc_id': 'PMC2717760', 'publication_date': {'year': 2009, 'month': 7, 'day': 20}, 'journal': 'J. Clin. Oncol.', 'full_journal_title': 'Journal of clinical oncology : official journal of the American Society of Clinical Oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 264, 'phenotypes': []}\n",
      "{'id': 676, 'name': 'EID676', 'description': 'The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.', 'disease': {'id': 134, 'name': 'Osteosarcoma', 'display_name': 'Osteosarcoma', 'doid': '3347', 'url': 'http://www.disease-ontology.org/?id=DOID:3347'}, 'drugs': [{'id': 326, 'name': 'Cisplatin', 'pubchem_id': None}], 'rating': 4, 'evidence_level': 'B', 'evidence_type': 'Predictive', 'clinical_significance': 'Resistance', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Mutation', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 430, 'name': 'Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.', 'citation': 'Caronia et al., 2009, Pharmacogenomics J.', 'citation_id': '19434073', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/19434073', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2009, 'month': 10}, 'journal': 'Pharmacogenomics J.', 'full_journal_title': 'The pharmacogenomics journal', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 264, 'phenotypes': []}\n",
      "{'id': 1076, 'name': 'EID1076', 'description': 'A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. ABCB1 C3435T carriers had a longer progression-free survival (p = 0.039) along with a tendency toward a longer overall survival (p = 0.093).', 'disease': {'id': 22, 'name': 'Breast Cancer', 'display_name': 'Breast Cancer', 'doid': '1612', 'url': 'http://www.disease-ontology.org/?id=DOID:1612'}, 'drugs': [], 'rating': 3, 'evidence_level': 'B', 'evidence_type': 'Prognostic', 'clinical_significance': 'Better Outcome', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Polymorphism', 'drug_interaction_type': None, 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 744, 'name': 'ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.', 'citation': 'Kim et al., 2012, Oncology', 'citation_id': '22906996', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/22906996', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2012}, 'journal': 'Oncology', 'full_journal_title': 'Oncology', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 263, 'phenotypes': []}\n",
      "{'id': 675, 'name': 'EID675', 'description': 'The mutation at codon 3435 (C>T) correlated with a significantly higher response rate to platinum-based chemotherapy in patients with advanced non small cell lung cancer (NSCLC).  103 Chinese patients with NSCLC were evaluated in this study. However, there was not a significant correlation between the mutation and overall survival.', 'disease': {'id': 8, 'name': 'Non-small Cell Lung Carcinoma', 'display_name': 'Non-small Cell Lung Carcinoma', 'doid': '3908', 'url': 'http://www.disease-ontology.org/?id=DOID:3908'}, 'drugs': [{'id': 326, 'name': 'Cisplatin', 'pubchem_id': None}, {'id': 93, 'name': 'Carboplatin', 'pubchem_id': None}], 'rating': 2, 'evidence_level': 'B', 'evidence_type': 'Predictive', 'clinical_significance': 'Sensitivity/Response', 'evidence_direction': 'Supports', 'variant_origin': 'Germline Mutation', 'drug_interaction_type': 'Substitutes', 'status': 'accepted', 'open_change_count': 0, 'type': 'evidence', 'source': {'id': 429, 'name': 'Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer.', 'citation': 'Yan et al., 2011, Asian Pac. J. Cancer Prev.', 'citation_id': '22296372', 'source_type': 'PubMed', 'asco_abstract_id': None, 'source_url': 'http://www.ncbi.nlm.nih.gov/pubmed/22296372', 'open_access': None, 'pmc_id': None, 'publication_date': {'year': 2011}, 'journal': 'Asian Pac. J. Cancer Prev.', 'full_journal_title': 'Asian Pacific journal of cancer prevention : APJCP', 'status': 'fully curated', 'is_review': False, 'clinical_trials': []}, 'variant_id': 263, 'phenotypes': []}\n"
     ]
    }
   ],
   "source": [
    "#       #Python Script                         #Input Variant List          #Sample Name\n",
    "%run -i 'identified_variants_to_annotation.py' 'test_annotate_variants.tsv' 'SCLC5'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
